Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Grebely

Showing results (201-210 of 368) with videos related to

Pageof 37
Sort By:
Hepatology (Baltimore, Md.)|April 5, 2013
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsNatasha K Martin, Peter Vickerman, Jason Grebely, et al.
Journal of Hepatology|September 15, 2020
High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, AustraliaHeather Valerio, Maryam Alavi, Matthew Law, et al.
The International Journal on Drug Policy|July 7, 2015
The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS studyEmmanuel Fortier, Maryam Alavi, Michelle Micallef, et al.
AIDS (London, England)|May 5, 2012
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infectionJason Grebely, Margaret Hellard, Tanya Applegate, et al.
The International Journal on Drug Policy|October 14, 2022
Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage studyHeather Valerio, Anna Conway, Maryam Alavi, et al.
Journal of Hepatology|December 1, 2019
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysisBehzad Hajarizadeh, Evan B Cunningham, Heather Valerio, et al.
European Journal of Gastroenterology & Hepatology|July 23, 2014
Delivery of treatment for hepatitis C virus infection in the primary care settingDavid Baker, Maryam Alavi, Amanda Erratt, et al.
Canadian Liver Journal|August 22, 2022
The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There"Michael L Cheng, Mohamed S Abdel-Hakeem, Sophie E Cousineau, et al.
Drug and Alcohol Review|August 9, 2023
Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage studySteven Hobday, Heather Valerio, Troy Combo, et al.
Plos One|November 27, 2013
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionJordan J Feld, Jason Grebely, Gail V Matthews, et al.
Pageof 37

Showing results (201-210 of 368) with videos related to

Sort By:
Pageof 37
Hepatology (Baltimore, Md.)|April 5, 2013
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsNatasha K Martin, Peter Vickerman, Jason Grebely, et al.
Journal of Hepatology|September 15, 2020
High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, AustraliaHeather Valerio, Maryam Alavi, Matthew Law, et al.
The International Journal on Drug Policy|July 7, 2015
The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS studyEmmanuel Fortier, Maryam Alavi, Michelle Micallef, et al.
AIDS (London, England)|May 5, 2012
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infectionJason Grebely, Margaret Hellard, Tanya Applegate, et al.
The International Journal on Drug Policy|October 14, 2022
Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage studyHeather Valerio, Anna Conway, Maryam Alavi, et al.
Journal of Hepatology|December 1, 2019
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysisBehzad Hajarizadeh, Evan B Cunningham, Heather Valerio, et al.
European Journal of Gastroenterology & Hepatology|July 23, 2014
Delivery of treatment for hepatitis C virus infection in the primary care settingDavid Baker, Maryam Alavi, Amanda Erratt, et al.
Canadian Liver Journal|August 22, 2022
The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There"Michael L Cheng, Mohamed S Abdel-Hakeem, Sophie E Cousineau, et al.
Drug and Alcohol Review|August 9, 2023
Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage studySteven Hobday, Heather Valerio, Troy Combo, et al.
Plos One|November 27, 2013
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionJordan J Feld, Jason Grebely, Gail V Matthews, et al.
Pageof 37